- Home
- SER vs MAIA Comparison
SER vs MAIA Comparison
Compare SER & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- MAIA
- Stock Information
- Founded
- SER 2017
- MAIA 2018
- Country
- SER United States
- MAIA United States
- Employees
- SER N/A
- MAIA N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- MAIA Health Care
- Exchange
- SER Nasdaq
- MAIA Nasdaq
- Market Cap
- SER 56.5M
- MAIA 46.7M
- IPO Year
- SER 2018
- MAIA 2022
- Fundamental
- Price
- SER $5.75
- MAIA $1.76
- Analyst Decision
- SER Strong Buy
- MAIA
- Analyst Count
- SER 1
- MAIA 0
- Target Price
- SER $11.00
- MAIA N/A
- AVG Volume (30 Days)
- SER 10.4K
- MAIA 209.6K
- Earning Date
- SER 05-08-2025
- MAIA 05-09-2025
- Dividend Yield
- SER N/A
- MAIA N/A
- EPS Growth
- SER N/A
- MAIA N/A
- EPS
- SER N/A
- MAIA N/A
- Revenue
- SER $51,000.00
- MAIA N/A
- Revenue This Year
- SER N/A
- MAIA N/A
- Revenue Next Year
- SER N/A
- MAIA N/A
- P/E Ratio
- SER N/A
- MAIA N/A
- Revenue Growth
- SER N/A
- MAIA N/A
- 52 Week Low
- SER $3.81
- MAIA $1.40
- 52 Week High
- SER $14.57
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- SER 54.81
- MAIA 46.37
- Support Level
- SER $5.01
- MAIA $1.71
- Resistance Level
- SER $6.00
- MAIA $1.81
- Average True Range (ATR)
- SER 0.32
- MAIA 0.11
- MACD
- SER 0.01
- MAIA -0.01
- Stochastic Oscillator
- SER 81.65
- MAIA 17.95
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.